Q BioMed (OTCMKTS:QBIO) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued on Friday, Zacks.com reports. The brokerage currently has a $0.50 price target on the stock. Zacks Investment Research‘s target price would suggest a potential upside of 16.28% from the company’s current price.
According to Zacks, “Q BioMed Inc. is a biomedical acceleration and development company. It focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. Q BioMed Inc. is based in New York. “
Separately, ValuEngine upgraded Q BioMed from a “hold” rating to a “buy” rating in a report on Thursday, August 1st.
Q BioMed (OTCMKTS:QBIO) last issued its earnings results on Tuesday, October 15th. The company reported ($0.17) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.12) by ($0.05). Analysts expect that Q BioMed will post -0.64 EPS for the current fiscal year.
Q BioMed Company Profile
Q BioMed Inc, a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company offers Strontium Chloride SR89, a radiopharmaceutical therapeutic for the treatment of bone cancer pain therapies. It is also developing Man-01, a pre-clinical lead candidate for the treatment of primary open angle glaucoma; BM-001 for the treatment of rare pediatric nonverbal autism spectrum disorder; and Uttroside-B for liver cancer.
Further Reading: Market Indexes
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Q BioMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Q BioMed and related companies with MarketBeat.com's FREE daily email newsletter.